放射治疗系统制造商安科锐（Accuray）正式任命医疗技术行业资深管理者Steve La Neve为首席执行官

药械VIP2025-11-05

礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地，以扩大口服药物产能，完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示，该投资计划将为南荷兰省创造500个高薪岗位，招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外，预计建设期间将新增约1500...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581401517?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-05 16:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2581401517","market":"us","top_or_hot":-1,"title":"放射治疗系统制造商安科锐（Accuray）正式任命医疗技术行业资深管理者Steve La Neve为首席执行官","media":"药械VIP","content":"<div>\n<p>礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地，以扩大口服药物产能，完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示，该投资计划将为南荷兰省创造500个高薪岗位，招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外，预计建设期间将新增约1500...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105174635a48a422d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>放射治疗系统制造商安科锐（Accuray）正式任命医疗技术行业资深管理者Steve La Neve为首席执行官</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n放射治疗系统制造商安科锐（Accuray）正式任命医疗技术行业资深管理者Steve La Neve为首席执行官\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-05 16:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105174635a48a422d&s=b><strong>药械VIP</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地，以扩大口服药物产能，完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示，该投资计划将为南荷兰省创造500个高薪岗位，招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外，预计建设期间将新增约1500...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105174635a48a422d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4592","symbol_name":"伊斯兰概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105174635a48a422d&s=b","article_id":"2581401517","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105174635a48a422d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581401517","pubTimestamp":1762330622,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"放射治疗系统制造商安科锐正式任命医疗技术行业资深管理者Steve La Neve为首席执行官，任命即时生效。Sarepta治疗公司两款已获批药物在一项关键临床试验中失败。Sarepta此次试验的对象是其疗法Amondys 45和Vyondys 53，试验目的是验证这两款疗法治疗杜氏肌营养不良症的有效性。这是全球首个且唯一获批用于该患者群体的治疗药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","UCB":"美国社区银行","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4007":"制药","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4211":"区域性银行","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","MTSR":"Metsera Inc.","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","NVO":"诺和诺德","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"translate_title":"Accuray, a manufacturer of radiotherapy systems, officially appoints Steve La Neve, a veteran manager in the medical technology industry, as CEO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9,"UCB":1,"MTSR":0.61},"content_text":"礼来宣布计划在荷兰卡特维克投资30亿美元新建生产基地，以扩大口服药物产能，完善公司全球供应链体系。该生产基地将承担其首款口服小分子GLP-1受体激动剂orforglipron的生产任务。公司计划于今年年底前向全球监管机构提交该药物的肥胖症治疗申请。礼来同时表示，该投资计划将为南荷兰省创造500个高薪岗位，招聘对象包括高技能工程师、科学家、运营专员及实验室技术人员。此外，预计建设期间将新增约1500个工作岗位，项目计划于明年动工。礼来和诺和诺德计划宣布与白宫达成新的药品定价协议，包括减肥药，以换取医疗保险对其产品的承保。根据协议，这两家公司将以每月149美元的价格提供各自最低剂量的肥胖症药物。协议可能在本周宣布。作为回报，这些药物将被纳入美国联邦医疗保险计划的覆盖范围，该计划面向65岁及以上的老年人，这将带来一系列新的巨大报销额度。为在对处于研发阶段的制药公司Metsera的竞购中击败竞争对手辉瑞(Pfizer)，诺和诺德(Novo Nordisk)正不断加大投入。Metsera周二表示，诺和诺德目前提出的收购报价最高可达100亿美元。这一金额高于其此前最高90亿美元的报价，而此前的报价已引发辉瑞提起诉讼。Metsera同时透露，辉瑞也对其今年9月提出的近49亿美元报价进行了调整，提高了前期支付的现金金额。辉瑞(Pfizer)公布2025年第三季度业绩。季度总营收166.54亿美元，上年同期为177.02亿美元，同比下降6%。季度持续业务营业利润35.5亿美元，上年同期为44.81亿美元，同比下降21%。季度归属公司普通股东的净利润35.41亿美元，上年同期为44.65亿美元，同比下降21%。放射治疗系统制造商安科锐（Accuray）正式任命医疗技术行业资深管理者Steve La Neve为首席执行官，任命即时生效。La Neve拥有超40年行业经验，此前担任Globus Medical创伤及关节重建业务总裁，并曾在美敦力、BD、Bone Biologics等企业担任高管。其接替的Suzanne Winter在任职六年CEO后退休，将转任顾问至11月。之江生物与三优生物医药（上海）有限公司签署战略合作协议，将围绕创新生物药的自动化开发展开深度合作。三优生物将对其抗体药物分子筛选工艺进行系统性自动化升级。此举不仅能够将科研人员从重复性操作中解放出来，使其更专注于高价值的创造性分析工作，还能凭借自动化工艺更高的精准度和稳定性，大幅提升研发预算的使用效率。体内细胞治疗领域创新企业微滔生物科技（上海）有限公司宣布完成超亿元人民币规模的天使轮融资。本轮融资由启明创投领投，融资资金将主要用于核心技术平台迭代优化以及首款候选产品在自身免疫疾病领域的临床转化和开发。Manifold Bio与罗氏达成战略合作和许可协议。双方将运用Manifold专有的组织靶向穿梭药物组合和mDesign人工智能驱动的体内发现引擎，开发新一代血脑屏障穿梭药物，用于治疗神经系统和神经退行性疾病。根据协议，Manifold主导研发新型血脑屏障穿梭载体，罗氏主导后续临床前、临床和商业化工作。罗氏将支付5500万美元首付款，如果一切顺利，许可协议的里程碑可能会超过20亿美元。Sarepta治疗公司两款已获批药物在一项关键临床试验中失败。Sarepta此次试验的对象是其疗法Amondys 45和Vyondys 53，试验目的是验证这两款疗法治疗杜氏肌营养不良症的有效性。Sarepta表示，此次试验结果不会影响这两款药物在市场上的可及性，并补充称计划与美国药品监管机构会面，商讨将这两款药物目前的加速批准转为完全批准。优时比（UCB）宣布，美国食品药品监督管理局（FDA）已批准KYGEVVI用于治疗胸苷激酶2缺陷症（TK2d）的成人及发病年龄在12岁或更早的儿科患者。这是全球首个且唯一获批用于该患者群体的治疗药物。美国生物技术企业联合治疗公司在纽约大学兰贡医学中心完成了将基因编辑猪肾移植至人体的首例临床试验手术，标志着这一手术的规模化临床试验正式启动。这是继此前多项“同情用药”个案移植手术后，首项由美国食品和药物管理局(FDA)批准的人体移植基因编辑猪肾规模化临床试验，旨在系统评估基因编辑猪肾用于终末期肾病患者的安全性和有效性。职业教练：药械VIP经理人职业陪跑1个月服务，助你找到新的职业起点与新工作；","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581401517","isCrawlerRequest":true}